Tislelizumab Plus Gemcitabine
Tislelizumab Plus Gemcitabine entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.
Timeline
Fri, 07 Aug 2026 16:21:02 GMTSino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC - AllSci
Mon, 03 Aug 2026 19:45:56 GMTTislelizumab Plus Gemcitabine Shows Efficacy in Cisplatin-Ineligible Urothelial Carcinoma - OncLive
Related explainers
Connected entities
China2 live mentionsCisplatin2 live mentionsIneligible Urothelial Carcinoma2 live mentionsSino Bio1 live mentionsNSCLC1 live mentionsAllSci Sino Bio1 live mentionsNSCLC AllSci AllSci1 live mentionsShows Efficacy1 live mentionsOncLive Tislelizumab Plus1 live mentionsGemcitabine Shows Efficacy1 live mentions
FAQ
What does this page track?
Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tislelizumab Plus Gemcitabine.
Why might this page be noindex?
Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.
Where should readers verify facts?
Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.
Source diversity
2 distinct publisher/source names are currently connected to this entity page.